Navigation Search

Latest Advances in Prostate Cancer Screening & Treatment


Call (718) 765-2500 To Make An Appointment With A Maimonides Cancer Specialist, Or Request An Appointment Online.


Prostate Cancer Screening & Treatment at Maimonides: Why choose us?

Maimonides Cancer Center in Brooklyn, NY, uses the latest medical and surgical advances to deliver exceptional care to patients with prostate cancer.  Maimonides Cancer Center, Brooklyn’s only full-service cancer center, earned the 2016 Outstanding Achievement Award by the Commission on Cancer of the American College of Surgeons - one of a select group of 22 accredited cancer programs across the nation to receive this honor, and one of only two in New York State. Our multidisciplinary teams of physicians, clinicians, and prostate cancer surgeons collaborate to provide personalized treatment plans for you or your loved one. 

Maimonides prostate cancer experts use some of the latest technologies and techniques for optimal patient outcomes, including:


Prostate Cancer Screening

Fusion biopsy offers new standards of diagnostic accuracy for prostate screening. This technique fuses pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real-time, for excellent delineation of the prostate and suspicious lesions. Other methods of prostate cancer screening, including prostate-specific antigen (PSA) tests and digital rectal exams (DRE), can be less reliable, leading to uncertainty for both patient and urologist. Prostate biopsy, the most reliable method of detection, can be a challenge because of the difficulties in visualizing the entirety of the prostate and location of the biopsy needle. 

Learn about prostate cancer screening at Maimonides >>


Prostate Cancer Treatment

Maimonides Cancer Center is one of the few hospitals in Brooklyn using an advanced treatment called Xofigo® (radium Ra 223 dichloride).  Maimonides prostate cancer specialists use Xofigo to treat prostate cancer that has spread to the bones and is resistant to treatments that lower testosterone, a condition called metastatic castration-resistant prostate cancer or mCRPC. Xofigo injections have been found to extend life by more than 30% for men (14.9 months in Xofigo-treated men vs 11.3 months in placebo-treated men, in an updated analysis) killing cancer cells in the bones with limited damage to healthy cells.

Learn about prostate cancer treatment at Maimonides >>